• 1. 国家自然科学基金（NO.82104767）；
• 2. 河北省中医药管理局科研计划项目（NO.B2025055）；
• 3. 首都医科大学临床专科学院（系）培养基金（NO.CCMU2024ZKYXY012）；
• 4. 西藏自治区自然科学基金组团式医疗援藏项目（NO. XZZR202402037(W)）；
• 5. 拉萨市重大科技计划项目（NO. LSKJ202521）；
• 6. 中华中医药学会青年人才托举工程项目（NO.CACM-2024-QNRC2-B20）；
• 7. 北京中医药新时代125工程托举人才（NO.20251250057）；

第一作者/通讯作者近五年发表学术论文：

1) Chen J*, Zhou H*, Liu H#, Li X#, Zong H, Zhang S, Li Y, Shi Y. Mechanism of Shenyuan Yiqi Huoxue capsule alleviating coronary microvascular  dysfunction: Network analysis and experimental evidence. Front Pharmacol 2025, 16: 1534967.（SCI，IF=4.8）

2) Li Y*, Duan J*, Liu H#, Lin S, Xu H, Li X#. Coronary microvascular dysfunction in post-PCI target vessels: a systematic  review and meta-analysis of prevalence and associated outcomes. Front Cardiovasc Med, 2025, 12: 1620204.（SCI，IF=2.9）

3) Zhou H*, Chen J*, Liu H#, Li X#, Zong H, Zhang S, Shi Y, Li Y. Traditional Chinese medicine injections with Tonifying Qi, equivalent effect of  regulating energy metabolism, for acute myocardial infarction: a systematic  review and meta-analysis of randomized clinical trials. Front Pharmacol, 2025, 16: 1511486.（SCI，IF=4.8）

4) Chen J, Shang J, Liu H, Li X#, Lai X, Lou Y, Zhou H. Comparative effectiveness and safety of four traditional Chinese medicine injections with invigorating blood circulation, equivalent effect of anticoagulation or antiplatelet in acute myocardial infarction: a Bayesian network meta-analysis [J]. Front. Pharmacol. 15:1400990. doi: 10.3389/fphar.2024.1400990 （SCI，IF=5.6）

5) Sun X*, Chen J*, Shang J, Liu H#, Li X#, Lou Y, Zhou H. Traditional chinese medicine injections with activating blood circulation,  equivalent effect of anticoagulation or antiplatelet, for acute myocardial  infarction: A systematic review and meta-analysis of randomized clinical trials [J]. Complement Ther Med, 2024, 82: 103039.（SCI，IF=3.5）

6) Zong H*, Hu Z*, Li W, Wang M, Zhou Q, Li X#, Liu H#. Electronic cigarettes and cardiovascular disease: epidemiological and biological  links[J]. Pfügers Archiv - European Journal of Physiology, 2024.（SCI，IF=4.5）

7) Li X, Zhang H Y, Shang J J, et al. Clinical Characteristics and Risk Factors of Periprocedural Myocardial Injury in  Patients with Elective PCI in a TCM Hospital[J]. Evid Based Complement Alternat Med, 2022,2022:7158740.DOI:10.1155/2022/7158740.（SCI，IF=2.629）

8) Li X, Zhang Y, Liu H X, et al. A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention[J]. Complement Ther Med, 2022,69:102841.DOI:10.1016/j.ctim.2022.102841.（SCI，IF=3.335）

9) Li X, Lou Y, Shang J J, et al. Traditional Chinese medicine injections with activating blood circulation,  equivalent effect of anticoagulation or antiplatelet, for acute myocardial  infarction: A protocol for the systematic review and meta-analysis of randomized  clinical trials[J]. Medicine (Baltimore), 2022,101(24):e29089.DOI:10.1097/MD.0000000000029089.（SCI，IF=1.817）

10) Xiang Li, Xiao-Lei Lai, Yu-Tong Fei, et al. Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedure myocardial injury following percutaneous coronary intervention: Study protocol for a randomized, double-blind, placebo-controlled trial.Ann Transl Med 2019;7(6):119（SCI，IF=3.689）

11) Li X, Shang J J, Sun X Y, et al. Recurrent coronary restenosis treated with Chinese medicine: A case report[J]. Chin J Integr Med, 2017.DOI:10.1007/s11655-017-2808-y.（SCI，IF=1.34）

12) 刘红旭, 尚菊菊, 李享. 新型冠状病毒感染合并心血管疾病中医诊疗方案[J]. 北京中医药, 2023,42(04):376-380.

13) 尚菊菊, 刘红旭, 李享. 基于指南/共识探讨中医/中西医结合防治冠心病的诊疗进展[J]. 北京中医药, 2023,42(09):939-942.

14) 李享, 尚菊菊, 刘红旭, 等. 基于PBL教学法以Morning Report为主要形式探索中医内科临床教学研究[J]. 新中医, 2023,55(08):218-222.

15) 李享, 刘红旭, 佘靖. 佘靖育阴解毒法治疗糖尿病的经验撷菁[J]. 中华中医药杂志, 2022,37(12):7149-7153.

16) 李享, 刘红旭, 佘靖, 等. 中药联合针刺治疗难治性心源性休克验案举隅[J]. 中华中医药杂志, 2022,37(07):3850-3854.

17) 李享, 何刚, 刘红旭, 等. 参元丹胶囊干预气虚血瘀证缺血性心力衰竭的随机、对照临床研究[J]. 世界中西医结合杂志, 2021,16(08):1481-1485.